R. Legg

发表

Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis.

D. Sclar, L. M. Robison, T. Skaer, 1998, The Journal of clinical psychiatry.

Antidepressant Pharmacotherapy: Economic Evaluation of Fluoxetine, Paroxetine and Sertraline in a Health Maintenance Organization

D. Sclar, L. M. Robison, T. Hughes, 1995, The Journal of international medical research.

Cost benefit of sumatriptan to an employer.

D. Sclar, J. Mackowiak, R. Legg, 1997, Journal of occupational and environmental medicine.

In-hospital mortality, length of stay, and hospitalization cost of COVID-19 patients with and without hyperkalemia

A. Amin, N. Rosenthal, A. Agiro, 2022, The American Journal of the Medical Sciences.

Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression

D. Sclar, L. M. Robison, R. S. Galin, 1995 .

Effect of pharmaceutical formulation of diltiazem on the utilization of medicaid and health maintenance organization services

D. Sclar, L. M. Robison, R. Legg, 1994 .

Antihypertensive pharmacotherapy: Economic outcomes in a health maintenance organization

D. Sclar, L. M. Robison, R. Legg, 1994 .

Ipratropium bromide in the management of chronic obstructive pulmonary disease: effect on health service expenditures.

D. Sclar, L. M. Robison, T. Skaer, 1994, Clinical therapeutics.

Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population.

K. Fox, J. Horton, F. Trudo, 2017, American health & drug benefits.

Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization.

D. Sclar, T. Hughes, T. Skaer, 1994, Clinical therapeutics.